China Successfully Implanted Retrievable Transcatheter Aortic Valve in Humans

China Successfully Implanted Retrievable Transcatheter Aortic Valve in Humans

The first human implantation of the VenusA Plus, retrievable valve system was successfully completed at the Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU) on November 27, 2017.

Venus Medtech has become China’s first company to provide a retrievable interventional cardiac valve system. Prof. Wang Jian’an, president of SAHZU, announced first successful human implantation of a retrievable transcatheter aortic valve.

The operation was conducted on 76 year old female patient who was diagnosed with severe aortic valve stenosis and defined as a high-risk surgical patient. The cardiology team discussed and defined the patient’s anatomical features as a bicuspid aortic valve and asymmetric calcification, which raised the risk of dislocation during the valve implantation. Retrievable system was the most suitable treatment for the patient, according to the physicians.

The retrievable system allows the valve to withdraw and reposition after release, avoiding adverse events, which occur as a result of a poor implant position and mismatch of the implanted valve. It includes valve translocation, severe paravalvular leakage, a negative impact on the bicuspid aortic valve, and high degree atrioventricular block caused by conduction bundle compression. The system also reduces the complexity of the procedure, which helps to promote the adoption and application of TAVR technology.

“SAHZU’s medical team was closely working with Zhejiang Province’s Cardiac Valve Research Institute and Venus Medtech’s R&D team to study, develop, and produce the heart valve products. The collaboration began with the VenusA-Valve and has led to the success for VenusA Plus,” said professor Wang. “The product is a next-generation TAVR valve that delivers good performance in terms of release, retrievable stability, controllability and passing ability, thus offering great potential when it comes to clinical applications.” Wang added.

The successful human implantation of VenusA Plus took place four months after the launch of China’s first TAVR valve VenusA-Valve. “Venus Medtech has continuously achieved technological breakthroughs. We plan to roll out more innovative products going forward, demonstrating the company’s strong competence in innovation and its ongoing commitment to serving patients,” said Zi Zhenjun, CEO of Venus Medtech.

You may be interested

Business

Global Metallic Couplings Market by Type, Deployment, Industry, Approach, and Geography- Forecast to 2026

Albert R - December 14, 2018

According to the new market research report on "Global Metallic Couplings Market Report 2018 - 2026” covers there Product Type, Region Coverage, Application or End-user, Industry Insights…

Business

Essential Insights to Know About the Global Mining Lubricant Market Report 2018

Albert R - December 14, 2018

According to the new market research report on "Global Mining Lubricant Market Report 2018 - 2026” covers there Product Type, Region Coverage, Application or End-user, Industry Insights…

Business

Global Metformin Hydrochloride Market – Statistics, Facts and Forecast to 2026

Albert R - December 14, 2018

According to the new market research report on "Global Metformin Hydrochloride Market Report 2018 - 2026” covers there Product Type, Region Coverage, Application or End-user, Industry Insights…

Most from this category